Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Earnings Data
Report Date
Mar 12, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.39Last Year’s EPS
-1.6Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in R&D ventures and strong financial management, offset by minimal revenue growth and reduced operational expenses. The company's strategic focus on innovative treatments and a solid cash position are promising, but current revenue generation and market penetration remain challenges.Company Guidance
Joint Venture with Hemispherian
BioLineRx established a JV with Hemispherian to develop GLIX1 for glioblastoma and other cancers, combining expertise in cancer drug discovery and regulatory success.
FDA Clearance for GLIX1
The FDA cleared Hemispherian's IND for GLIX1, with plans to initiate a Phase I/IIa trial for glioblastoma in Q1 2026.
Strong Cash Position
BioLineRx ended Q3 2025 with $25.2 million in cash and equivalents, sufficient to fund operations into the first half of 2027.
Positive Interim Results for Sickle Cell Disease
An investigator-initiated trial showed positive results for motixafortide in sickle cell disease, with a presentation planned at the ASH Annual Meeting.
Reduction in Net Loss
Q3 2025 net loss was $1 million, compared to $5.8 million in Q3 2024, primarily due to reduced expenses following the Ayrmid out-licensing transaction.
BLRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BLRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 24, 2025 | $3.25 | $3.50 | +7.69% |
Aug 14, 2025 | $3.94 | $3.77 | -4.31% |
May 27, 2025 | $3.66 | $3.68 | +0.55% |
Mar 31, 2025 | $3.05 | $2.96 | -2.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bioline RX Ltd Sponsored ADR (BLRX) report earnings?
Bioline RX Ltd Sponsored ADR (BLRX) is schdueled to report earning on Mar 12, 2026, Before Open (Confirmed).
What is Bioline RX Ltd Sponsored ADR (BLRX) earnings time?
Bioline RX Ltd Sponsored ADR (BLRX) earnings time is at Mar 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLRX EPS forecast?
BLRX EPS forecast for the fiscal quarter 2025 (Q4) is -0.39.